Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of subcutaneous anifrolumab in chronic and/or subacute cutaneous lupus erythematosus
CTR20244793Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anifrolumab in cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE), sponsored by AstraZeneca. Started Jul 2025; status: active.
02
Drugs
anifrolumab
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on CTR20244793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244793.